Amicus Therapeutics’ (FOLD) “Hold” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Amicus Therapeutics (NASDAQ:FOLD) in a report published on Friday,Benzinga reports.

FOLD has been the subject of a number of other research reports. Wall Street Zen upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Zacks Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Citigroup started coverage on shares of Amicus Therapeutics in a report on Wednesday. They issued a “buy” rating and a $17.00 price objective for the company. JPMorgan Chase & Co. boosted their target price on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Amicus Therapeutics in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.36.

Amicus Therapeutics Price Performance

Amicus Therapeutics stock opened at $14.20 on Friday. The business’s 50 day simple moving average is $9.48 and its 200 day simple moving average is $7.82. Amicus Therapeutics has a 12 month low of $5.51 and a 12 month high of $14.36. The company has a market cap of $4.38 billion, a price-to-earnings ratio of -354.81 and a beta of 0.46. The company has a current ratio of 2.99, a quick ratio of 2.09 and a debt-to-equity ratio of 1.70.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.The business had revenue of $169.06 million during the quarter, compared to the consensus estimate of $165.24 million. During the same period last year, the business posted $0.10 earnings per share. The business’s revenue for the quarter was up 19.5% on a year-over-year basis. Sell-side analysts forecast that Amicus Therapeutics will post 0.15 EPS for the current year.

Insider Activity

In other Amicus Therapeutics news, insider David Michael Clark sold 25,643 shares of the firm’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $11.00, for a total value of $282,073.00. Following the completion of the transaction, the insider directly owned 271,332 shares of the company’s stock, valued at $2,984,652. This trade represents a 8.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jeff Castelli sold 76,158 shares of the business’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $10.16, for a total transaction of $773,765.28. Following the transaction, the insider owned 439,318 shares of the company’s stock, valued at $4,463,470.88. This trade represents a 14.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 319,808 shares of company stock valued at $3,293,653. 2.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Amicus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. raised its holdings in shares of Amicus Therapeutics by 211.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 3,497 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Amicus Therapeutics by 167.6% in the first quarter. Russell Investments Group Ltd. now owns 142,569 shares of the biopharmaceutical company’s stock worth $1,163,000 after purchasing an additional 89,287 shares during the last quarter. Hsbc Holdings PLC raised its stake in Amicus Therapeutics by 20.4% in the first quarter. Hsbc Holdings PLC now owns 50,456 shares of the biopharmaceutical company’s stock valued at $412,000 after purchasing an additional 8,536 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Amicus Therapeutics in the first quarter valued at approximately $53,000. Finally, Capital Fund Management S.A. lifted its position in Amicus Therapeutics by 408.8% during the first quarter. Capital Fund Management S.A. now owns 312,561 shares of the biopharmaceutical company’s stock valued at $2,550,000 after purchasing an additional 251,134 shares during the last quarter.

Amicus Therapeutics News Summary

Here are the key news stories impacting Amicus Therapeutics this week:

• Positive Sentiment: BioMarin to acquire Amicus for ~$4.8B ($14.50 per share), citing complementary marketed products (Galafold, Pombiliti + Opfolda), $599M of recent revenue and expectations the deal will be accretive to non‑GAAP EPS within 12 months — this provides a clear exit price and strategic rationale that pushed the stock up. Article Title
• Positive Sentiment: BioMarin’s press release emphasizes revenue upside from bringing Amicus products into BioMarin’s global footprint and resolving pending patent litigation on Galafold — details that support the acquisition valuation and near-term revenue accretion view. Article Title
• Neutral Sentiment: Trading was temporarily halted pre-market for “news pending,” then resumed around the acquisition announcement — a procedural sign the market treated the item as material. (Trading halt noted in market alerts.)
• Neutral Sentiment: Cantor Fitzgerald reaffirmed a “neutral” rating with a $14.50 price target (roughly in line with the deal price), and Needham reiterated a “hold” — analyst stances imply limited upside beyond the announced offer price absent a competing bidder. Article Title
• Negative Sentiment: Two investor‑rights firms (Halper Sadeh LLC and The Ademi Firm) announced investigations into whether the $14.50 per‑share sale is fair to Amicus shareholders — litigation or proxy fights could delay closing, pressure timing, or open the door to a higher bid/renegotiation, increasing deal execution risk. Article Title
• Negative Sentiment: Insider selling disclosures (including recent sales by the CEO and another officer) surfaced in filings earlier this week — while not unusual, these sales add a note of caution for some investors evaluating management alignment ahead of the deal. Article Title

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.